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Specific metabolic pathways are activated by
different nutrients to adapt the organism to available
resources. Although essential, these mechanisms
are incompletely defined. Here, we report that
medium-chain fatty acids contained in coconut oil,
a major source of dietary fat, induce the liver
u-oxidation genesCyp4a10 andCyp4a14 to increase
the production of dicarboxylic fatty acids. Further-
more, these activate allu- and b-oxidation pathways
through peroxisome proliferator activated receptor
(PPAR) a and PPARg, an activation loop normally
kept under control by dicarboxylic fatty acid degra-
dation by the peroxisomal enzyme L-PBE. Indeed,
L-pbe/mice fed coconut oil overaccumulate dicar-
boxylic fatty acids, which activate all fatty acid oxida-
tion pathways and lead to liver inflammation, fibrosis,
and death. Thus, the correct homeostasis of dicar-
boxylic fatty acids is a means to regulate the efficient
utilization of ingested medium-chain fatty acids, and
its deregulation exemplifies the intricate relationship
between impaired metabolism and inflammation.
INTRODUCTION
The liver plays a critical role in lipid metabolism with multiple
enzymatic pathways controlling lipid uptake, modifications,
catabolism, as well as lipid biosynthesis and export. The routes
followed by fatty acids to reach the liver and the adaptation of
liver lipid metabolism differ according to fatty acid chain length.
Following their uptake by enterocytes, long- and very-long-chain
fatty acids (RC14) are re-esterified into triglycerides and incor-
porated into chylomicrons. These are transported via lymph ves-
sels into the blood to distribute fatty acids to peripheral tissues.248 Cell Reports 5, 248–258, October 17, 2013 ª2013 The AuthorsChylomicron remnants are eventually taken up by the liver
(Williams, 2008). In contrast to this indirect pathway, medium-
chain fatty acids (C8–C12) are taken up by enterocytes and
directly transported through the hepatoportal circulation to the
liver for uptake and degradation (Papamandjaris et al., 1998).
Thus, hepatocytes must be able to cope with rapid and poten-
tially massive influxes of medium-chain fatty acids. Coconut
oil, a major source of fat for millions of people living mainly in
tropical areas, but also an important component of several pro-
cessed foods, consists mainly of medium-chain fatty acids with
a particularly high abundance of lauric acid (Kumar, 2011). The
impact of coconut oil feeding on health is still debated. Because
it contains high amounts of saturated fat, it is considered poten-
tially harmful for health. On the other hand, many studies indicate
that it has beneficial effects (DebMandal and Mandal, 2011;
Houssay andMartı´nez, 1947). The lack of knowledge concerning
the molecular mechanisms and physiology associated with co-
conut oil consumption still prevents a clear understanding of
its potential impact on health.
In a previous study aimed at identifying lipid metabolic
pathways associated with resistance to coconut oil high-fat
(HFD-CO)-induced hepatic steatosis and liver inflammation, we
identified the peroxisomal enzyme enoyl-CoA hydratase/L-3-hy-
droxyacyl-CoA dehydrogenase (Ehhadh) (also called L-peroxi-
somal bifunctional enzyme, L-pbe, the term used in this study)
as a potential protection gene (Hall et al., 2010). L-PBE catalyzes
the second and third steps of peroxisomal b-oxidation, reactions
also catalyzedby the enzymeD-PBE (D-peroxisomal bifunctional
enzyme, Hsd17b4) (Reddy and Hashimoto, 2001). Whereas
D-PBE is constitutively expressed, L-PBE is inducible (Wanders
and Waterham, 2006), and the enzymes have different substrate
specificities. Genetic inactivation of Hsd17b4 induces growth
retardation and prevents very-long-chain fatty acid oxidation
and bile acid maturation (Baes et al., 2000). In contrast, mice
with genetic inactivation of L-pbe have no obvious phenotype
(Qi et al., 1999), and the range of substrates for this enzyme is
not fully established. Here, we investigated the specific role of
Figure 1. L-pbe/ Mice Develop Fulminant Liver Failure When Fed a HFD-CO but Not HFD-L
(A) Growth curves of WT and L-pbe/ mice on normal chow (NC) and HFD-L. NC group: WT, n = 10; L-pbe/ n = 12. HFD-L: WT, n = 10; L-pbe/ n = 8.
(B) Change in body weight of WT (n = 5) and L-pbe/ (n = 8) mice fed a HFD-CO.
(C) Survival curve of WT (n = 9) and L-pbe/ (n = 13) mice fed a HFD-CO.
(D) Livers from WT and L-pbe/ mice fed a HFD-CO.
(E) Hematoxylin and eosin staining.
(F) F4/80 immunostaining.
(G) Masson’s trichrome staining.
(H) a-Smooth muscle actin immunostaining of liver sections. Scale bars, 100 mm.
(I) Blood levels of aspartate (AST), alanine (ALT) aminotransferases, and bilirubin.
(J and K) Hepatic expression levels of (J) mRNAs for proinflammatory cytokines and (K) fibrosis markers. Values are means ± SEM, n = 6.
(L) Analysis of the fatty acid content of the three different diets; HFD-CO is highly enriched in medium-chain fatty acids with lauric acid representing about 50%
total fatty acids.
See also Figures S1, S2, and S3.L-PBE in theadaptation toHFD-CO feedinganddemonstrated its
role in regulating the amount of medium-chain dicarboxylic fatty
acids, which are essential activators of all fatty acid oxidation
pathways and whose accumulation correlates with liver failure.
RESULTS
Coconut Oil, but Not Lard, Induces Weight Loss and
Death in L-pbe/ Mice
L-pbe/mice fed a normal chow (NC) are phenotypically indis-
tinguishable from their wild-type littermates (Qi et al., 1999)C(Figure 1A, for body weight). However, when fed a HFD-CO
diet, the L-pbe/ mice rapidly lost weight and most of them
died within 3 weeks, whereas wild-type mice gained weight
and remained healthy (Figures 1B and 1C). In initial studies, we
also compared wild-type with L-pbe+/ and L-pbe/ litter-
mates. No phenotype could be observed in HFD-CO-fed he-
terozygous mice, and in the rest of the study we only compared
wild-type and L-pbe/ mice.
Because mouse milk is rich in C16 and C18 triglycerides
(Smith et al., 1968) and L-pbe/ mice grew normally during
the suckling period, the lipid species rather than the amount ofell Reports 5, 248–258, October 17, 2013 ª2013 The Authors 249
fat absorbed may have caused death of the L-pbe/ mice. To
test this hypothesis, we fed L-pbe/ mice a lard-based HFD
(HFD-L) and saw that these mice gained weight normally and
remained healthy (Figure 1A). These results indicate that L-pbe
is required selectively for the adaptation to HFD-CO.
Fulminant Liver Failure in HFD-CO-Fed L-pbe/ Mice
To assess the cause of death in HFD-CO-fed L-pbe/mice, we
analyzed them shortly before death, when they were severely
sick or when their original body weight was reduced by 25%.
Histological examination of different organs revealed no abnor-
malities in heart, lung, kidneys, or stomach (Figure S1). However,
the livers of the HFD-CO-fed mice were larger (Figure 1D) and
characterized by hepatocyte ballooning, macrophage infiltra-
tion, and increased fibrosis as revealed by collagen and smooth
muscle actin staining (Figures 1E–1H). Increased hepatocyte
proliferation and apoptosis were also visible (Figures S2A and
S2B). The presence of liver failure was confirmed by the strongly
increased plasma levels of aspartate (AST) and alanine (ALT)
aminotransferases and of bilirubin (Figure 1I). Liver inflammation
was associated with increased expression of the mRNAs for the
inflammatory cytokines tumor necrosis factor a (Tnfa), monocyte
chemoattractant protein 1 (Mcp-1), and interleukin-1b (Il-1b)
(Figure 1J). Increased expression of the mRNAs for alpha
smooth muscle actin (a-Sma), transforming growth factor beta
1 (Tgfb1), and collagen type I alpha 1 (Col1a1) confirmed devel-
opment of fibrosis (Figure 1K). Total liver triglycerides, free
cholesterol, and cholesteryl esters were not different between
HFD-CO-fed control and L-pbe/ mice (Figures S2C and
S2D). Biochemical analysis of the plasma of HFD-CO-fed
L-pbe/ mice showed higher concentrations of TNFa and
MCP-1 as well as slightly increased cholesterol and free fatty
acid (FA) levels, elevated LDL and diminished HDL, and hypogly-
cemia, with normal insulin levels (Table S1).
Presence of oxidative stress was demonstrated by increased
hepatic levels of the lipid peroxidation products 4-hydroxynone-
nal (4-HNE) and malondialdehyde (MDA) (Figures S2E and S2F)
and by increased expression of antioxidant, phase II genes,
including the glutathione-related enzymes (glutathione reduc-
tase [Gsr], glutathione S-transferase m1 and m3 [Gstm1 and
Gstm3], glutamate-cysteine ligase catalytic subunit [Gclc],
heme oxygenase-1 [Hmox1], and the NAD[P]H:quinone oxidore-
ductase 1 [Nqo1]) (Figure S2G). Ceramides, which are also asso-
ciated with oxidative stress, as well as glycosylceramides,
showed markedly elevated levels in the livers of HFD-CO-fed
L-pbe/mice, whereas sphingomyelin levels were normal (Fig-
ures S2H and S2I). The sphingolipid synthesis genes, including
subunits of serine palmitoyltransferases (Spt1 and Spt2), cer-
amide synthases 4 and 6 (CerS4 and CerS6), ceramide d(4)-de-
saturase (Des1), and the glucosylceramide synthase (Gcs) were
also markedly elevated (Figure S2J).
No alteration in liver histology, evidence of liver damage,
increased inflammation, or fibrosis could be observed in
L-pbe/ mice fed for 2 weeks with a lard-based HFD (Table
S1; Figures S3A–S3G).
Collectively, these data indicated that death of HFD-CO-fed
L-pbe/ mice was a consequence of liver inflammation,
fibrosis, and failure but was not associated with liver steatosis.250 Cell Reports 5, 248–258, October 17, 2013 ª2013 The AuthorsFurthermore, none of these effects were seen when mice were
fed a lard-based HFD.
L-pbe Deficiency Leads to Dicarboxylic Fatty Acid
Accumulation
Lipidomic analysis of NC, HFD-CO, and HFD-L (Figure 1L)
showed absence of very-long-chain FAs (>C20) in either diet;
long-chain FAs (C16 and C18) were the major species in
HFD-L and NC, whereas HFD-CO predominantly consisted of
the medium-chain fatty acids (MCFAs) decanoic (C10), lauric
(C12), and myristic (C14) acids with lauric acid representing
50% of total FAs.
As a first step to identify why the HFD-CO caused the
observed liver phenotype, we assessed the expression of key
enzymes involved in fatty acid oxidation, i.e., in mitochondrial
and peroxisomal b-oxidation and in microsomal u-oxidation. In
NC-fed mice, mitochondrial b-oxidation (medium-chain acyl-
CoA dehydrogenase [Mcad], long-chain acyl-CoA dehydroge-
nase [Lcad], and trifunctional protein alpha subunit [Hadha]),
peroxisomal b-oxidation (acyl-coenzyme A oxidase 1 [Acox1],
Hsd17b4, thiolase B [Acaa1b]), and microsomal u-oxidation
(cytochrome P450 family 4 subfamily a polypeptide 10 and 14,
Cyp4a10 and Cyp4a14) genes were expressed at similar levels
in wild-type and L-pbe/ mice (Figure 2A). After 2 days of
HFD-CO feeding, there was a small increase in the expression
of the peroxisomal b oxidation gene Acaa1b and a strong induc-
tion of u-oxidation genes in the L-pbe/ mouse livers (Fig-
ure 2B). After long-term HFD-CO feeding, all the mitochondrial,
peroxisomal, and microsomal fatty acid oxidation (FAO) genes
were significantly induced (Figure 2C).
The above data show that among the genes tested Cyp4as
were the first and most induced genes. These encode micro-
somal cytochromes (CYP4A10 and CYP4A14) that are respon-
sible for the first step in the production of dicarboxylic fatty acids
(DCAs) by u-oxidation (Hardwick, 2008). Lipidomic analysis
revealed a striking accumulation of DCAs in the livers of HFD-
CO-fed L-pbe/mice with dodecanedioic acid (C12DCA) being
the most induced species, both after 2 days or long-term HFD-
CO feeding (Figures 2D–2F). Figure S4A shows the relative
amounts of the different DCA species extracted from livers of
wild-type mice fed a HFD-CO. No accumulation of lauric acid
was seen in the livers of L-pbe/ mice fed a NC or a HFD-CO
(Figures S4B and S4C), and no difference in hepatic acyl-CoA
or phospholipid contents could be observed in control or
L-pbe/ mice (Figures S4D and S4E).
Thus, the immediate increase in Cyp4a expression and the
accumulation of dicarboxylic fatty acids were early events in
the liver pathology. As DCAs are normally degraded in the perox-
isomes (Suzuki et al., 1989), these data suggested that L-PBE
was required for their degradation. Previous studies have indeed
proposed that DCAs are preferential substrates for L-PBE (Dirkx
et al., 2007; Ferdinandusse et al., 2004; Houten et al., 2012;
Nguyen et al., 2008). These studies have been performed using
C10, C14, C16, andC20DCAs as substrates. Here, wemeasured
the rate of degradation of C12DCA in liver homogenates from
wild-type and L-pbe/ mice. This analysis showed a signifi-
cantly higher rate of degradation of C12DCA in control as
compared to L-pbe/ liver homogenates (Figure 2G), with faster
Figure 2. HFD-CO Induces Fatty Acid b- and u-Oxidation Pathways and the Accumulation of DCAs in the Livers of L-pbe/ Mice
(A–C) mRNA levels of fatty acid oxidation genes were measured in the livers of (A) NC-fed mice, (B) after 2 days of HFD-CO feeding, and (C) after long-term HFD-
CO feeding.
(D–F) DCA accumulation in the livers of NC or HFD-CO-fed mice corresponding to (A)–(C), respectively. Values are means ± SEM (n = 6), *p < 0.05, **p < 0.01, and
***p < 0.001.
(G andH) (G) Degradation rate of dodecanedioic acid (C12DCA) and (H) appearance of its degradation product adipic acid (C6DCA) in liver homogenates fromWT
and L-pbe/ mice. One representative out of three independent experiments is shown.
Values are means ± SEM (n = 3), **p < 0.01 and ***p < 0.001. See also Figure S4 and Table S1.rates of appearance of the C12DCA degradation products C10,
C8, C6, C4, and C3DCAs as shown for adipic acid (C6DCA) (Fig-
ure 2H; data not shown) (Jin and Tserng, 1991).
To provide an independent indication of the role of medium-
chain fatty acids in inducing liver failure, we fed wild-type and
L-pbe/ mice for 5 days with a NC complemented with 25%
glyceryl trilaurate. In L-pbe/ mice. This induced body weight
loss, alteration of liver histology, increased plasma AST and
ALT, increased hepatic expression of phase II and sphingolipid
synthesis genes, of the inflammatory and fibrosis markers
Tnfa, Mcp1, Il-1b, Tgfb1, a-Sma, and Col1a1, as well as of
Cyp4a10 and Cyp4a14 (Figures 3A–3H). These defects were
also associated with increased hepatic accumulation of DCAs
(Figure 3I). Importantly, DCAs larger than C12 were induced byCglyceryl trilaurate feeding, showing that the induction ofu-oxida-
tion mobilizes fat from sources other than the C12 triglyceride.
Together, the above observations indicate that the toxic effect
of coconut oil on L-pbe/ mouse livers is replicated by lauric
acid feeding and is associated with the rapid accumulation of
DCAs, which are normally degraded by L-PBE.
Lauric Acid and DCAs Activate Peroxisome Proliferator
Activated Receptors and Fatty Acid Oxidation Pathways
The fatty acid oxidation genes measured in Figures 2A–2C are
typical peroxisome proliferator activated receptor (PPAR) tar-
gets (Pyper et al., 2010). To determine whether HFD-CO indeed
induced a greater activation of PPARs in L-pbe/ thanwild-type
mice, we transfected the liver of mice using a hydrodynamicell Reports 5, 248–258, October 17, 2013 ª2013 The Authors 251
Figure 3. Glyceryl-Trilaurate-Supplemented Normal Chow Diet Induces Liver Damage in L-pbe/ Mice
(A–G) WT and L-pbe/ mice were fed a NC complemented with glyceryl trilaurate for 5 days and the following analysis were performed. (A) Change in body
weight. (B) Hematoxylin and eosin staining of liver sections. (C) PlasmaAST and ALT levels. (D) Hepatic expression of phase II genes. (E) Sphingolipid biosynthesis
genes. (F) mRNAs for proinflammatory cytokines. (G) Fibrosis markers of WT and L-pbe/ mice.
(H) Cyp4a10 and Cyp4a14 expression levels.
(I) Hepatic accumulation of DCAs.
Values are means ± SEM (n = 6), *p < 0.05, **p < 0.01, and ***p < 0.001.delivery system with a plasmid containing a peroxisome prolifer-
ator response elements (PPREs) driving the expression of a lucif-
erase reporter gene. Mice were then fed a NC or HFD-CO, and
luciferase activity was monitored on 3 consecutive days. Lucif-
erase activity was much higher in HFD-CO-fed L-pbe/ mice
than wild-type mice, whereas there was no difference in lucif-
erase activity between the two types of mice on NC (Figures
4A and 4B).
Because the PPRE reporter plasmid used in these experi-
ments can be activated by PPARa and PPARg, we assessed
the hepatic expression of PPARs under the different feeding
conditions. Figures 4C–4E show that upon HFD-CO feeding
expression of PPARa in the livers of L-pbe/ mice was un-
changed; PPARb/d was induced only after long-term HFD-CO
feeding, and PPARg expression was rapidly induced in 2 days
and much more after long-term feeding. This suggests that the
in vivo transcriptional response (Figure 4A) may be controlled
by different PPARs at different times after initiation of HFD-CO
feeding.
To determine whether lauric acid and DCAs were activators of
PPARs, we performed a transactivation assay using Gal4-ligand
binding domain-luciferase reporter constructs. We found that
lauric acid could induce PPARa and PPARg transcriptional activ-
ity, and also mildly activate PPARb/d (Figure 4F). Furthermore,
we showed that C12DCA and C16DCA could activate both252 Cell Reports 5, 248–258, October 17, 2013 ª2013 The AuthorsPPARa and PPARg (Figure 4G). Molecular modeling of the bind-
ing mode of C12DCA and C16DCA to the ligand binding sites of
human PPARs showed a more optimal binding of C16DCA than
C12DCA or lauric acid to PPARa and PPARg. This involves one
carboxylate group binding the polar head of the ligand binding
domain (S317, H351, H477, and Y501 in PPARg) with the other
carboxylate possibly interacting with R308; this double interac-
tion of carboxylates is more difficult to establish with the shorter
C12DCA (Figures S5A and S5B). Due to the strong sequence
identity among important residues of the human and the mouse
isoforms of the proteins (see Table S2), we can expect that the
differences in the calculated binding modes found between iso-
forms of human PPARs will be conserved between isoforms of
mouse PPARs.
Collectively, these data show that lauric acid and DCAs can
activate PPARa and PPARg and that PPARg expression is
rapidly induced in the liver of HFD-CO-fed L-pbe/ mice.
Thus, in the absence of L-PBE-dependent degradation of
DCAs, these induce a feedforward mechanism to increase the
PPAR-dependent expression of all fatty oxidation pathways.
DCAs Mediate the Toxic Effect of Coconut Oil
To determine if DCAs mediate the toxic effect of coconut oil, we
fed L-pbe/ mice with C12DCA-supplemented NC. After a
4 day feeding period, L-pbe/ mice lost more than 6 g of
Figure 4. HFD-CO, Lauric Acid, and DCAs Activate PPARa and PPARg
(A) Luciferase activity measured inWT or L-pbe/mice expressing a PPRE-luciferase reporter construct in their liver and fed a NC or HFD-CO. Luciferase activity
was recorded at the indicated times after transfection of the reporter construct.
(B) Quantification of the luciferase activity. Data aremeans ±SEM, n = 5 for the NC groups and n = 7 for the HFD-CO groups. *p < 0.05, **p < 0.01, and ***p < 0.001.
(C–E) Expression of PPARa, PPARb/d, and PPARg in the liver of WT or L-pbe/mice fed a NC or HFD-CO, as indicated. Values are means ± SEM (n = 6), *p <
0.05, **p < 0.01, and ***p < 0.001.
(F and G) Transactivation of the mentioned PPAR (ligand binding domain of mouse PPARa, mouse PPARb/d, or human PPARg) reporter constructs by (F) lauric
acid and (G) C12 and C16 DCAs.
Values are means ± SEM (n = 4), *p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S5 and Table S2.body weight, whereas wild-type mice lost 1 g (Figure 5A). His-
tological analysis demonstrated severe liver damage in the
L-pbe/ mice as well as massively increased plasma AST and
ALT levels (Figures 5B–5D). This was also associated with
marked induction of the liver mRNAs for phase II proteins, sphin-
golipid synthesis enzymes, and cytokines (Figures 5E–5G). In
agreement with the transcriptional regulatory activity of DCAs,
1 day of C12DCA-supplemented diet feeding inducedmitochon-
drial, peroxisomal, and microsomal FAO pathways (Figures 5H–
5J), with a striking >30-fold induction of L-pbe in wild-type
mouse livers supporting that L-PBE is a major enzyme required
for adaptation to this DCA feeding. Also remarkable was theC60- to >100-fold induction of Cyp4as in L-pbe/ mice, further
supporting our proposal that DCAs induce a positive feedback
loop between CYP4A enzymatic products and expression of
these enzymes.
To test whether inhibiting DCA production would prevent liver
failure, we fed L-pbe/mice for 3 weeks a HFD-CO with simul-
taneous treatment with 1-aminobenzotriazole (ABT), an inhibitor
of CYP4As (Isayama et al., 2003; Kaikaus et al., 1993; Kroetz and
Xu, 2005). This treatment suppressed the production of DCAs
(Figure 6A), allowed survival of the mice (Figure 6B), and pro-
tected them against liver failure, as shown by their normal
plasma AST and ALT levels (Figure 6C) and normal liver histologyell Reports 5, 248–258, October 17, 2013 ª2013 The Authors 253
Figure 5. C12DCA-Supplemented Normal Chow Induces Liver Failure in L-pbe/ Mice
(A–G) Four days after initiation of C12DCA feeding, liver failure was evident as shown by the following. (A) Loss of body weight. (B) Liver histology. (C and D)
Plasma AST and ALT levels. (E) Antioxidant genes expression. (F) Sphingolipid synthesis gene expression. (G) Cytokine gene expression. Scale bars, 100 mm.
Values are means ± SEM (WT, n = 5; L-pbe/, n = 7–12), *p < 0.05, **p < 0.01, and ***p < 0.001.
(H–J) Fatty acid oxidation gene expression in the liver of WT and L-pbe/mice fed a NC or a C12DCA-supplemented NC diet for 1 day. Values are means ± SEM
(n = 6). WT NC versus WT C12DCA, *p < 0.05, **p < 0.01, and ***p < 0.001; L-pbe/ C12DCA versus WT C12DCA, #p < 0.05, ##p < 0.01, and ###p < 0.001.(Figure S6A). The treatment also prevented the induction of
phase II, sphingolipid synthesis, and inflammatory cytokines
genes (Figures S6B–S6D).
As ABT may also inhibit other enzymes than CYP4As, we
specifically silenced their activity by tail vein injection of small
interfering RNA (siRNAs) directed toward Cyp4a10 and
Cyp4a14 mRNAs. This treatment suppressed both Cyp4a10
and Cyp4a14 expression (Figure 6D) and the production of
DCAs (Figure 6E) and markedly improved the survival of HFD-
CO-fed L-pbe/ mice (Figure 6F). This treatment also pre-
vented liver damage as revealed by normal liver histology,
plasma AST, and ALT levels and absence of induction of phase
II, sphingolipid synthesis, and inflammatory cytokines genes
(Figures S6E–S6I).
Finally, as a further control that DCAs are the downstream
product of CYP4As that are relevant to the phenotype, we fed
L-pbe/ mice a C12DCA-supplemented diet and simulta-
neously treated them with ABT. L-pbe/ mice with or without
ABT treatment showed similar phenotypes after 3 day
C12DCA-supplemented diet feeding as shown by their similar
loss in body weight (Figure S6J), showing that ABT prevents
the liver phenotype through inhibition of CYP4A-dependent
DCA synthesis.
The above data confirm our model that DCA production by
CYP4A activity in HFD-CO-fed L-pbe/ mice leads to hepatic
failure and death.254 Cell Reports 5, 248–258, October 17, 2013 ª2013 The AuthorsDISCUSSION
Here, we describe a liver regulatory mechanism that is required
to prevent the dietary toxicity of MCFAs. This mechanism (Fig-
ure 6G) involves the induction by MCFAs of CYP4As leading to
an increased production of DCAs. These activate, in a PPARa/
PPARg-dependent manner, the expression of CYP4As as well
as the expression of mitochondrial and peroxisomal fatty acid
b-oxidation genes. We show that genetic inactivation of the
peroxisomal enzyme L-PBE leads to intracellular DCA accumu-
lation, inflammation, fibrosis, and liver failure. Thus, our data
suggest that the balance between DCA production by CYP4As
and their degradation by L-PBE is a mechanism that normally
fine-tunes hepatic b- and u-oxidation activities in response to
MCFA absorption. An imbalance between these mechanisms
may cause massive nutrient-induced inflammation.
Several beneficial effects of MCFAs as compared to long-
chain fatty acids have been described when added as food
complement, notably a reduction of different aspects of the
metabolic syndrome (Papamandjaris et al., 1998; St-Onge
et al., 2003, 2008), in part by increasing energy expenditure
and reducing fat mass and by preventing development of insulin
resistance (Rubin et al., 2000; Turner et al., 2009). The way by
which MCFAs increase energy expenditure and FAO appears
to be related to their ability to activate PPARs. Two recent re-
ports demonstrated that MCFAs can activate PPARg, PPARa,
Figure 6. Preventing DCA Production by Suppressing CYP4A Activity Protects against Liver Failure
(A–C)WT or L-pbe/mice were fed a HFD-CO and treated with the CYP4 inhibitor ABT or with PBS. (A) ABT treatment suppressed DCA formation, (B) protected
the mice from death, and (C) normalized plasma AST and ALT levels. PBS group: WT, n = 5; L-pbe/, n = 11. ABT group: WT, n = 5; L-pbe/, n = 13.
(D) Western blot analysis of CYP4A10 and mRNA level of Cyp4a14 in the livers of fasted mice treated with Cyp4a specific or control siRNAs.
(E and F) DCA levels (E) and survival curves (F) of HFD-CO-fed L-pbe/mice treated withCyp4a specific or control siRNAs. L-pbe/, n = 9; L-pbe/ +RNAi, n =
12. Values are means ± SEM. **p < 0.01.
(G) Schematic description of the mechanism by which coconut oil (MCFAs) induces CYP4A-dependent production of DCAs. DCAs then activate a feedforward
mechanism to further activate the three fatty oxidation pathways. This feedforward loop is normally regulated by L-PBE-dependent DCA degradation. In the
absence of L-PBE, accumulation of DCAs leads to liver failure through the induction of inflammation and fibrosis.
See also Figure S6.and PPARb/d and can reduce adipogenesis in a cellular model of
adipocyte differentiation (Liberato et al., 2012; Malapaka et al.,
2012). In agreement with these publications, we show that lauric
acid can transactivate PPARa and PPARg and, consequently,
liver FAO pathways in the liver (Patsouris et al., 2006; Peters
et al., 2003). We show that feeding of mice with glyceryl trilaurate
induces u-oxidation of other fat sources than the C12 triglycer-
ide. This suggests that the pathway of u-oxidation of MCFAs is
used to stimulate reduction of fat mass in general and is not
only a specific mechanism to deal with MCFAs.
The transcriptional response to lauric acid includes increased
expression of Cyp4as, which preferentially use this fatty acid as
a substrate to initiate its conversion to dodecanedioic
acid (C12DCA) (Adas et al., 1999; Hardwick, 2008). In the
absence of the L-PBE, a DCA degrading enzyme, there is accu-
mulation of DCAs in the liver. These are good transcriptional
activators of both PPARa and PPARg, providing an explanation
for the observation that DCAs can induce FAO (Fan et al., 1998;
Lundgren et al., 1992). Also, as compared to lauric acid, DCAs
are relatively better activators of PPARg than PPARa, and
C16DCA is more potent than C12DCA. This can be understoodCin the context of our results showing that MCFAs induce
u-oxidation from a variety of fat sources increasing DCAs of all
chain lengths. It is remarkable that the induction of L-pbe and
Cyp4as in vivo by C12DCA feeding of wild-type mice was about
40- and >100-fold, respectively. This was a more robust induc-
tion than seen in the in vitro PPRE-luciferase reporter assay, sug-
gesting that some of the DCAs or other oxidation intermediates
produced in vivo by the C12DCA-induced u-oxidation pathway
are better activators of PPARs. Less likely, it could be that the
sensitivity of the luciferase reporter assay is less than the sensi-
tivity of the endogenous transcription regulatory system. Also,
because HFD-CO feeding increases expression of Pparb/d and
Pparg, the full activation by DCAs of FAO pathways involves
the combined control of PPAR expression and transcriptional
activity.
Thus, our data indicate that rapidly after coconut oil, or glyc-
eryl trilaurate ingestion, MCFAs absorbed by the liver first acti-
vate PPARa. This is rapidly followed by induction of microsomal
u-oxidation and formation of DCAs. These then more strongly
activate PPARa and PPARg, whose expression becomes mark-
edly induced. This feedforward loop accelerates induction ofell Reports 5, 248–258, October 17, 2013 ª2013 The Authors 255
FAO pathways (Figure 6G). These observations suggest that for-
mation of DCAs by u-oxidation upon MCFA feeding is an adap-
tive mechanism to rapidly induce all FA disposal mechanisms.
Under normal conditions, only 10%–20% of the MCFAs
absorbed by the liver are channeled through microsomal
u-oxidation (Bjo¨rkhem, 1978; Handler and Thurman, 1988),
supporting that this may be a regulatory rather than a major
degradation pathway. It is interesting to note that DCAs have
been proposed as potential drugs for diabetes treatment (Min-
grone et al., 2012). Our data suggest that this may be mediated
by their capacity to induce PPAR transcriptional activity and acti-
vate all FAO pathways.
An important aspect of our study is the demonstration that
accumulation of DCAs caused by the genetic inactivation of
L-pbe leads to massive inflammation, fibrosis, and liver failure.
The mechanisms by which DCAs, or some of their metabolites,
induce this reaction, is still unknown. However, earlier studies
showed that medium-chain DCAs can inhibit mitochondrial
respiration and reduce ATP production by affecting electron
transfer reactions (Passi et al., 1984; Tonsgard and Getz,
1985), thus favoring reactive oxygen species (ROS) production.
Increased peroxisomal b-oxidation also contributes to the pro-
duction of ROS. This oxidative stress may explain the accumula-
tion of lipid peroxidation products, which are chemoattractants
for inflammatory cells (Curzio et al., 1985). Increased ceramide
production is also a sign of cellular stress and inflammation (Bik-
man and Summers, 2011), and ceramides can uncouple oxida-
tive phosphorylation leading to increased leakage of electrons
to generate ROS and induce apoptosis (Corda et al., 2001; Li
et al., 2010). Thus, the inflammatory and fibrotic response to
HFD-CO feeding may combine several, cross-amplifying
mechanisms.
Whether the deregulation of this adaptive mechanism may
cause liver diseases in humans is still to be discovered. However,
a recent study reported association of SNPs in the L-PBE gene
with elevated fasting serum insulin and plasma glucose levels
(Banasik et al., 2011), parameters that are highly influenced by
inflammation (Glass and Olefsky, 2012), and a genome-wide
association study identified CYP4A as a risk locus for hepatic
steatosis (Suhre et al., 2011). Further studies in humans may
uncover a clearer link between MCFA-rich diets and liver inflam-
mation in the context of individual genetic susceptibilities. It is,
however, interesting to note that MCAD deficiency, a disease
caused by homozygous inactivation of the mitochondrial me-
dium-chain acyl-CoA dehydrogenase gene (MCAD or ACADM),
can cause acute hypoketotic hypoglycemia, lethargy, seizures,
and coma leading to sudden death, a condition that is associ-
ated with hepatomegaly, acute liver disease, and urine secretion
of C6, C8, and C10DCAs (Feillet et al., 2003; Schatz and Ensena-
uer, 2010). This condition is favored by fasting suggesting that, in
absence of MCAD, MCFAs are channeled to CYP4As to
generate excessive DCAs causing conditions similar to that
observed in HFD-CO-fed mice.
Thus, collectively, our data show that the physiological
function of the peroxisomal enzyme L-PBE is to degrade
medium-chain dicarboxylic acids whose role is to induce all
FAO pathways in response to MCFA feeding. This represents
an unsuspected mechanism required to adapt liver metabolism256 Cell Reports 5, 248–258, October 17, 2013 ª2013 The Authorsto the ingestion of a specific type of lipid. This also demonstrates
that impaired medium-chain fatty acid metabolism may rapidly
induce an inflammatory reaction that can have fatal
consequences.
EXPERIMENTAL PROCEDURES
Mice and Diets
L-pbe/ mice from a mixed 129/Ola-C57Bl/6 background have been previ-
ously described (Qi et al., 1999). For our initial studies, L-pbe/ mice were
crossed with C57Bl/6 mice to generate L-pbe+/mice, which were then inter-
crossed to obtain L-pbe+/+(WT), L-pbe+/, and L-pbe/ littermates. Mice
were maintained at 24C on a 12-hr/12-hr-light/dark cycle (7:00–19:00), with
free access to water and NC (3436 from Provimi Kliba AG) and were used
when 6–8 weeks old. Only male mice were used for the experiments presented
here. For HFD feeding, mice were fed with coconut-oil-based HFD (HFD-CO)
or lard-based HFD (HFD-L) (D12331 and D12492 from Research Diets). The
customized diets were prepared by grinding the normal chow (3436 from
Provimi Kliba) and mixing with glyceryl trilaurate (Yacoo) to 25% (w/w) and do-
decanedioic acid (C12DCA) (Sigma-Aldrich) to 10% (w/w).
L-pbe/ mice fed a HFD-CO were killed when they were severely sick
(markedly reducedmobility and feeding behavior) or had lost 25%of their orig-
inal body weight (long-term feeding). Wild-type mice were killed after 21–
24 day feeding. In feeding experiments, all mice were killed in the fed state.
Blood samples were collected by heart puncture in EDTA and aprotinin
(Sigma-Aldrich). Liver samples were rapidly dissected, weighed, frozen in
liquid nitrogen, and stored at 80C. All animal studies were approved by
the Veterinary Office of Canton de Vaud, Switzerland.
1-Aminobenzotriazole (ABT) (Sigma-Aldrich) was dissolved in PBS and gav-
aged at 100 mg/kg/day, which has been shown to be effective to inhibit lauric
acid hydroxylase activity in mice (Isayama et al., 2003; Kaikaus et al., 1993). All
treatments started simultaneously with the food shift.
Histology and Immunohistochemistry
Livers were fixed with 4% paraformaldehyde and embedded in paraffin, and
5 mmsections were prepared for hematoxylin and eosin orMasson’s trichrome
staining. Immunofluorescence microscopy was performed using antibodies
against F4/80 (Abcam), a-smooth muscle actin (Sigma-Aldrich), Ki67 (Abcam),
cleaved caspase 3 (Cell Signaling Technology), and 4-HNE (Jaica) according
to the manufacturer’s instructions. Malondialdehyde (MDA) was measured
with the TBARS Assay Kit by following manufacturer’s protocol (Cayman
Chemical). Other tissues were examined with similar procedures.
Analysis of Dicarboxylic Acids
Extraction and analysis of dicarboxylic fatty acids was adapted from Kushnir
et al. (2001). Briefly, 15 mg of ground liver tissue was resuspended in 1 ml
H2O. One hundred microliters of an internal standard (1 mmol/l methyl malonic
acid [MMA]) and 3ml of MTBE containing 30ml/l phosphoric acid were added.
Samples were vortexed for 5 min and centrifuged. The supernatant was trans-
ferred to a new glass tube and dried under a flow of nitrogen. One hundred
sixty microliters of HCl (3 M) in 1-butanol was added. The mixture was incu-
bated at 50C for 5 min. Samples were dried under nitrogen and then resus-
pended with 300 ml methanol containing 50 ml/l ammonium formate. Analysis
of dicarboxylic fatty acids was achieved by a liquid chromatography system
equippedwith anUptisphere Strategy C18-2 high-performance liquid chroma-
tography (HPLC) column (Interchim) coupled to a Varian 320-MS triple quad-
rupole mass spectrometer (Agilent Technologies) or a TSQ Vantage triple
quadrupole mass spectrometer (Thermo). Mass spectrometer settings of
selected dicarboxylic fatty acids are shown in Table S3.
RNA Extraction and Real-Time PCR
Total RNA was prepared from livers using RNA Stat-60 according to the man-
ufacturer’s instructions (Amsbio). First-strand cDNA was synthesized from
2.5 mg of total RNA using random primers (Promega) and Superscript II reverse
transcriptase (Invitrogen). Real-time PCR was performed using Power SYBR
Green Master Mix (Applied Biosystems). All reactions were normalized to
b2-microglobulin (B2M) levels. Specificmouse primers for each gene are listed
in Table S4.
Analysis of Fatty acyl-CoAs
Fatty acyl-CoAs were extracted from 15 mg ground liver tissue. Each sample
was resuspended in 200 ml water and spiked with 10 ml of an internal standard
mix (100 pmol of C15:0-, C17:0-, C23:0-, C25:0-CoA, Avanti Polar Lipids).
Fatty acyl-CoA extraction and analysis were performed as described (Haynes
et al., 2008). HPLC separation was achieved on a Gemini C18 column (150 3
2 mm column size, 5 mm particle size, Phenomenex). Mass spectrometry anal-
ysis was done on a Varian 320-MS Triple QuadrupoleMass Spectrometer (Agi-
lent Technologies) equipped with an ESI source. Mass spectrometer settings
of selected fatty acyl-CoAs are listed in Table S5.
Luciferase Assay in Cell Culture
Gal4-ligand binding domain of mouse PPARa, mouse PPARb/d, or human
PPARg plasmids were gifts from B. Staels (Universite´ Lille Nord de France,
Lille, France) and Johan Auwerx (E´cole polytechnique fe´de´rale de Lausanne).
The 5x-UAS-TK-Luc was purchased from Promega. The NIH 3T3mouse fibro-
blasts in 12-well plates were transiently transfected with 0.8 mg of DNA: Gal4-
LBD, 5x-UAS-TK-Luc, and CMV Renilla. Lauric acid and C12DCA were
dissolved in sodium hydroxide for the stock solution (100 and 200mM, respec-
tively), bound to fatty-acid-free BSA (1 mM fatty acid to 1% BSA), and then
added to the medium for 24 hr. Luciferase assay was performed with Dual-
luciferase reporter assay system (Promega). Firefly luciferase activity was
normalized to CMV Renilla luciferase.
Hydrodynamic Injection
The hydrodynamic injection was performed as previously described with small
modifications (Bell et al., 2007). Briefly, 10 mg/ml PPRE (L-pbe promoter,
position 2952 to 2918)-luciferase plasmid (Bardot et al., 1993) (generously
provided by C. Carlberg) solution was prepared and intravenously injected in
5 s to the mice based on body weight (10% v/w). After injection and full re-
covery, mice were divided into NC- and HFD-CO-fed groups. Mice were
then injected with luciferin and anesthetized with isoflurane, and luciferase
activity was measured using an in vivo bioluminescence imaging system
(Xenogen IVIS 3D, Caliper).
b-Oxidation Measurements
b-Oxidation measurements were described elsewhere (Hall et al., 2010) with
small modifications. Mice were fasted for 24 hr before liver collection.
C12DCA (0.5 mM) was added to the reactions, which were incubated at
37C and then snap frozen in liquid nitrogen at different time points. Fatty
acid oxidation or formation rates were analyzed after lipid profiling.
In Vivo siRNA Treatment
RNAi siRNA duplexes (Ambion and Invitrogen) complementary to theCyp4a10
and Cyp4a14 genes were complexed with Invivofectamine 2.0 (Invitrogen)
according to manufacturer recommendation before the injection. For each
gene, two to four siRNAs with different sequences were tested, and that
yielding maximal suppression was selected for the experiments. An equimolar
mix of the two Cyp4a siRNAs or control siRNA was injected intravenously
through the tail vein of 6-week-old mice at a dose of 7 mg/kg. After
7–10 days HFD-CO feeding, the same injection was performed again.
Statistics
Statistical analysis was performed with Student’s t test. Quantitative data are
expressed asmean±SEM. p values less than 0.05were considered significant.
Other statisticalmethodswerementioned and indicatedwhere theywere used.
For additional details, see the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and five tables and can be found with this article online at http://dx.
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Supplemental Information
EXTENDED EXPERIMENTAL PROCEDURES
Biochemical Analysis
Plasma TNFa, IL-1b, and MCP-1 were determined using Mouse Cytokine/Chemokine Panel (Millipore, Zug, Switzerland). AST and
ALT were measured by enzymatic tests (Roche Applied Science, Basel, Switzerland) using a Hitachi robot 902.
Triglyceride Levels in Liver
Mouse liver (50 mg) was homogenized in chloroform:methanol (2:1) solution. Distilled water was added and mixed vigorously with
the homogenate. After centrifugation, solvent phase was kept for the next column separation steps. SPE columns were purchased
from Laubscher labs (Miecourt, Switzerland). Lipid extracts were eluted by chloroform, followed by drying and reconstitution with
chloroform. For the determination of concentration, we used the Triglyceride enzymatic PAP 150 kit (Biomerieux, Geneva,
Switzerland) by following the instructions.
Chemicals and Lipid Standards
DLPC 12:0/12:0 (850335), PE 17:0/14:1 (PE31:1, LM-1104), PI 17:0/14:1 (PI31:1, LM-1504), PS 17:0/14:1 (PS31:1, LM-1304), C17:0
Ceramide (860517), C12:0 SM (860583), Glucosyl C8:0 Cer (860540) were used as internal lipid standards and were purchased from
Avanti Polar Lipids Inc (Alabaster, Alabama, USA). Ergosterol was used as sterol standard and was purchased from Fluka (Buchs,
Switzerland). Methylmalonic acid (MMA), hydrogen chloride (3M in 1-butanol) and LCMS grade ammonium formate were purchased
from Sigma-Aldrich. Phosphoric acid (85 wt % solution in water) was from Acros Organics (Thermo Scientific).
MTBE was from Fluka (Buchs, Switzerland). Methylamine (33% in absolute ethanol) was from Sigma-Aldrich. HPLC grade chlo-
roform was purchased from Acros Organics. LC-MS grade methanol and LC-MS grade ammonium acetate were from Fluka. LC-
MS grade water was purchased from Biosolve (Valkenswaard, Netherlands).
Lipid Extraction Protocols
Lipid extracts were prepared using the MTBE protocol (Matyash et al., 2008). Briefly, 15 mg ground liver tissue was resuspended in
100 ml H2O. The suspension was transferred into a 2 ml Eppendorf tube. 360 ml methanol and a mix of internal standards were added
(400 pmol DLPC, 1000 pmol PE31:1, 1000 pmol PI31:1, 3300 pmol PS31:1, 2500 pmol C12SM, 500 pmol C17Cer and 100 pmol
C8GC). Samples were vortexed and 1.2 ml of MTBE was added. Samples were placed for 10 min on a multitube vortexer at 4C
(Lab-tek International, Christchurch, New Zealand) followed by an incubation for 1 hr at room temperature (RT) on a shaker. Phase
separationwas induced by addition of 200 ml MS-gradewater. After 10min of incubation at RT samples were centrifuged at 1000 g for
10 min. The upper (organic) phase was transferred into a 13 mm glass tube with a Teflon-lined cap and the lower phase was reex-
tracted with 400 ml artificial upper phase (MTBE /methanol / H2O 10:3:1.5). In total 1500 ml of organic phase was recovered from each
samples, split into three parts and dried in a CentriVap VacuumConcentrator (Labconco, MO, USA). One part was treated by alkaline
hydrolysis to enrich for sphingolipids and the other two aliquots were used for glycerophospholipid/phosphorus assay and sterol
analysis, respectively.
Glycerophospholipids were deacylated according to the method by Clarke (Clarke and Dawson, 1981). Briefly, 1 ml freshly pre-
pared monomethylamine reagent (methylamine/H2O/n-butanol/methanol at 5:3:1:4 (vol/vol)) was added to the dried lipid extract
and then incubated at 53C for 1 hr in a water bath. Lipids were cooled to RT and then dried. For desalting, the dried lipid extract
was resuspended in 300 ml water-saturated n-butanol and then extracted with 150 ml H2O. The organic phase was collected, and
the aqueous phase was reextracted twice with 300 ml water-saturated n-butanol. The organic phases were pooled and dried in a
CentriVap Vacuum Concentrator.
Determination of Total Phosphorus
The dried total lipid extract was resuspended in 250 ml chloroform/methanol (1:1) and 50 ml were placed into a 13 mm disposable
pyrex tube. The solvent was completely evaporated and 0, 2, 5, 10, 20 ml of a 3mMKH2PO4 standard solution were placed into sepa-
rate pyrex tubes. To each tube 20 ml of water and 140 ml of 70%perchloric acid were added. Samples were heated at 180C for 1 hr in
a hood. Tubes were then removed from the block and kept at RT for 5 min. Then 800 ml of freshly prepared H2O / 1.25% NH4-
Molybdate (100 mg / 8 ml H2O) / 10% ascorbic acid (100 mg / 6 ml H2O) in the ratio of 5:2:1 were added. Tubes were heated at
100C for 5 min with a marble on each tube to prevent evaporation. Tubes were cooled at RT for 5 min. 100 ml of each sample
was then transferred into a 96-well microplate and the absorbance at 820 nm was measured.
Phospho- and Sphingolipid Analysis by Tandem Mass Spectrometry
Tandemmass spectrometry for the identification and quantification of phospho- and sphingolipid molecular species was performed
usingmultiple reactionmonitoring (MRM)with a TSQVantage Triple StageQuadrupoleMass Spectrometer (Thermo Fisher Scientific)
equipped with a robotic nanoflow ion source, Nanomate HD (Advion Biosciences, Ithaca, NY). Each individual ion dissociation
pathway was optimized with regard to collision energy. Lipid concentrations were calculated relative to the relevant internal stan-
dards and then normalized to the total phosphate content of each total lipid extract.
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Sterol Analysis by Gas Liquid Chromatography Mass Spectrometry
Extracts were analyzed by GC–MS as described (Guan et al., 2010). Briefly, samples were injected into a VARIAN CP-3800 gas chro-
matograph equipped with a Factor Four Capillary Column VF-5 ms 15 m3 0.32 mm i.d. DF = 0.10 and analyzed by a Varian 320-MS
triple quadrupole (Agilent Technologies) with electron energy set to – 70 eV at 250C. Samples were applied with the column oven at
45C, held for 4 min, then raised to 195C (20C / min). Sterols were eluted with a linear gradient from 195 to 230C (4C / min), fol-
lowed by raising to 320C (10C / min). Finally, the column temperature was raised to 350C (6C / min) to elute sterol esters. Choles-
terol and cholesterol esters were identified by their retention times (compared to standards) and fragmentation patterns, which were
compared to the NIST library.
Analysis of Total Fatty Acids
Normal chow (NC), coconut oil enriched high-fat diet (HFD-CO) and lard high-fat diet (HFD-L) were extracted with the MTBE lipid
extraction protocol. Lipids were resuspended in 0.6 ml 14% boron trifluoride (BF3) in methanol (Sigma-Aldrich) and vortexed. The
tubes were incubated at 90C for 4 min in a water bath and then placed on ice. The solution was transferred to an eppendorf
tube and 100 ml of saturated NaCl solution was added. After vortexing 400 ml of hexanewas added. The solution was vortexed, centri-
fuged (3000 g, 5min) and the upper phasewas transferred to a glass tube. The lower phasewas reextracted twice with hexane (400 ml
hexane and 200 ml hexane). The combined upper phases were dried with nitrogen. The dried lipids were resuspended in 500 ml hex-
ane and further diluted 1:20 for GC-MS analysis. Samples were injected into a VARIAN CP-3800 gas chromatograph equipped with a
Factor Four Capillary Column and analyzed by a Varian 320-MS triple quadrupole (Agilent Technologies). Samples were applied with
the column oven at 45C, held for 4 min, then raised to 130C (20C / min). Fatty acid methyl esters were eluted with a linear gradient
from 130 to 205C (3C / min) followed by a final temperature rise to 350C (40C / min). Esterified fatty acids were identified by their
retention times compared to the GLC-40 and GLC-50 FAME mix standards (Sigma-Aldrich) and by matching their mass spectra to
the NIST library.
Molecular Modeling
The docking of C12 and C16 in the ligand binding domain of PPARa, b/d and g was performed using three different software: Auto-
dock 4 (Morris et al., 2009), Autodock Vina (Trott andOlson, 2010), and a developmental algorithm called ‘‘Attracting cavities’’ that will
be implemented in EADock (Grosdidier et al., 2009, 2011). In brief, in the latter, an extended conformation of the ligand isminimized in
the cavities of the protein, starting from different positions and orientations, in an approach similar to that of MCSS (Miranker and
Karplus, 1991). Minimized poses are finally clustered and ranked according to the scoring function of EADock (Zoete et al., 2010).
A detailed description of this algorithm will be the subject of a future communication.
All docking runs were performed using experimental X-ray structures of the binding domain of human PPARa (PDB [Rose et al.,
2013] ID 1K7L [Xu et al., 2001]), PPARb/d (PDB ID 3SP9 [Jin et al., 2011[), and PPARg (PDB ID 3V9Y [Furukawa et al., 2012]), after
removing the ligand. The experimental binding assays on PPARa and PPARb/dwere done using mouse proteins. However, since no
experimental structure of a mouse PPAR is available, and in view of the high sequence conservation between the same isoforms of
mouse and human PPARs in the ligand binding domain (92 to 96%), all docking runs were performed using experimental 3D struc-
tures of the latter. All residues mentioned to play a role in the predicted binding modes of C12 and C16 are conserved in the same
isoforms of the mouse and human proteins.
Dockings were performed in a 253 A˚3 cubic box centered on the center of the ligand originally present in the PDB files. The so-
defined search spaces cover entirely the binding pocket of PPAR, including the pocket entrance(Zoete et al., 2007). Autodock cal-
culations were performed using 100 GA runs, each involving a maximum of 120500’000 energy calculations. Vina calculations were
performed using an exhaustiveness value of 100. Default values were used for all other parameters.
Since Arg280 of PPARg, respectively Arg271 in PPARa, is flexible and adopts different conformation in the 1K7L and 3V9Y exper-
imental structures, two additional docking runs were performed, in which the 1K7L conformation of this residue was adopted in the
3V9Y structure, and vice versa. The corresponding residue in PPARb/d, i.e., His244, is surrounded by other PPAR residues that pre-
vent conformational changes.
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Figure S1. Hematoxylin and Eosin-Stained Sections from Heart, Lung, Kidney, and Stomach, Related to Figure 1
Scale bar, 100 mm.
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Figure S2. Oxidative Stress and Ceramide Accumulation in the Liver of HFD-CO-Fed L-pbe/ Mice, Related to Figure 1
(A) Hepatocyte proliferation (Ki67 labeling) and (B) apoptosis (caspase 3 stained cells) in livers of HFD-CO fed WT and L-pbe/ mice, Scale bar, 100 mm.
(C and D) (C) Triglyceride and (D) cholesterol levels in the livers from mice fed HFD-CO. Values are means ± SEM, n = 6.
(E) Immunohistochemical detection of 4-hydroxynonenal (4-HNE) protein adducts. Scale bar, 5 mm.
(F) Hepatic malondialdehyde (MDA) content.
(G) Hepatic expression of antioxidant phase II genes.
(H and I) Hepatic concentrations of (H) ceramides, (I) glycosylceramides and sphingomyelins.
(J) mRNA levels of sphingolipid biosynthesis genes.
Values are means ± SEM (n = 6-8, each group), *p < 0.05, **p < 0.01 and ***p < 0.001.
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Figure S3. Lard-Based HFD-L Does Not Induce Liver Damage in L-pbe/ Mice, Related to Figure 1
(A) Livers from WT and L-pbe/ mice fed a HFD-L for 14 days.
(B) Hematoxylin and eosin staining.
(C) F4/80 immunostaining.
(D) a-smooth muscle actin immunostaining. Scale bars, 100 mm.
(E–F) (E) Blood levels of aspartate (AST) and alanine (ALT) aminotransferases, and hepatic expression levels of mRNAs for (F) proinflammatory cytokines, and (G)
fibrosis markers.
Values are means ± SEM, n = 6.
S6 Cell Reports 5, 248–258, October 17, 2013 ª2013 The Authors
Figure S4. Lipidomic Analysis of the Livers of WT and L-pbe/ Mice Fed NC or HFD-CO, Related to Figure 2
(A) Relative DCA levels in wild-type mice fed with normal chow or HFD-CO for short or long term.
(B and C) Fatty acids converted to their fatty acid methyl esters (FAMEs) after lipid extraction of livers from mice fed a normal chow (B) or a HFD-CO (C).
(D and E) Fatty acyl-CoAs (D) and total phospholipids (E) from livers of mice fed a long-term HFD-CO.
PC, phosphatidylcholine. PE, phosphatidylethanolamine. PI, phosphatidylinositol. PS, phosphatidylserine. Values are means ± SEM, n = 4.
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Figure S5. Predicted Binding Mode of DCA for the Ligand Binding Domain of Human PPARg, Related to Figure 4
(A) Hypothetical bindingmode of C12DCA to PPARg showing that the reduced size of C12DCAmakes simultaneous interaction with both R308 and the polar part
of the binding site more difficult.
(B) C16DCA is shown in magenta and PPARg as a tan ribbon, with important residues displayed in ball and stick. In this hypothesized binding mode, one
carboxylate function of C16DCA binds the polar head of the ligand binding domain constituted by residues S317 (S280 in PPARa and T253 in PPARb/d), H351
(Y314 in PPARa and H287 in PPARb/d), H477 (H440 in PPARa and H413 in PPARb/d) and Y501 (Y464 in PPARa and Y437 in PPARb/d). The second carboxylate
function is predicted to make ionic interactions with R308 (R271 in PPARa and H244 in PPARb/d). The aliphatic part of C16DCA extends in the hydrophobic
binding pocket of PPAR, and exists by making non-polar interactions with G312 (C275 in PPARa). In PPARb/d, R308 of PPARg is replaced by H244, which is
already involved in an ionic interaction with E223, and is made inaccessible to an interaction with C16DCA due to the replacement of G312 in PPARg by a bulky
R248 in PPARb/d. The latter is also involved in ionic interactions with E223, and is not available to interact favorably with C16DCA. The lack of an available ionic
interaction partner for the second carboxylate function of C16 and C12 DCA in PPARb/d could explain the inactivity of these compounds on the latter. All of the
above-mentioned residues are conserved in the mouse proteins, as listed in Table S2.
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Figure S6. Inhibiting DCA Production by Suppressing CYP4As Prevents Liver Failure in L-pbe/ Mice, Related to Figure 6
(A–D) Wild-type and L-pbe/mice were fed a HFD-CO diet and treated with ABT or PBS before collecting their livers for the following analysis: (A) Histology. (B)
Phase II gene expression. (C) Sphingolipid biosynthesis gene expression. (D) Proinflammatory cytokine gene expression. PBS group:WT, n = 5; L-pbe/, n = 11.
ABT group: WT, n = 5; L-pbe/, n = 13.
(E–I) siRNA-mediated knockdown ofCyp4as prevents development of liver failure in HFD-CO fed L-pbe/mice. (E) Liver histology of mice treated with a control
siRNA (L-pbe/) or Cyp4a-specific siRNA (L-pbe/+RNAi). (F) Plasma AST and ALT levels. (G) Antioxidant genes expression. (H) Sphingolipid synthesis genes
expression. (I) Cytokine gene expression. Scale bar, 100 mm. L-pbe/, n = 9; L-pbe/ +RNAi, n = 12.
(J) Change in body weight of L-pbe/ mice fed with a C12DCA-supplemented NC and simultaneously treated with saline or ABT.
Values are means ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001.
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